Welcome to our dedicated page for Cullinan Therapeutics news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Therapeutics stock.
Cullinan Therapeutics, Inc. develops clinical-stage therapies for autoimmune diseases and cancer, with a pipeline centered on T cell engagers and targeted oncology programs. Recurring news includes updates on CLN-978, a CD19xCD3 T cell engager for autoimmune diseases; velinotamig, a BCMAxCD3 program; CLN-049, a FLT3xCD3 bispecific T cell engager for relapsed or refractory AML and MDS; and zipalertinib for EGFR exon 20 insertion-mutated non-small cell lung cancer.
Company announcements commonly cover clinical data presentations, regulatory submissions and FDA communications, portfolio prioritization, collaborations involving zipalertinib, quarterly financial results, cash runway commentary and healthcare investor conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the presentation of initial clinical data for its drug CLN-619 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2-6. CLN-619 is a novel antibody targeting MICA and MICB, ligands that interact with immune cells to induce anti-tumor responses. The Phase 1 study focuses on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of CLN-619, both as a standalone treatment and in combination with pembrolizumab, in patients with advanced solid tumors. The clinical data presentation will take place on June 3, 2023, and aims to showcase the therapeutic potential of CLN-619 across various cancer types.